GRO [AGRIA] 6-K: (Original Filing)

[Agria Reports Financial Results for the Six Months Ended December 31, 2012 Beijing, China March 13, 2013 Mr. Alan Lai, Agria's Chairman of the Board, commented, I am pleased to see continued improvement inPGWs performance year on year. PGW reported improved profits and strong net cash inflow from operating and investing activities which led to]

By | 2016-01-10T15:11:30+00:00 March 13th, 2013|Categories: Chinese Stocks, GRO, SEC Original|Tags: , , , , , |0 Comments

GRO [AGRIA] 6-K: Agria Reports Financial Results for the Six Months

[Agria Reports Financial Results for the Six Months Ended December 31, 2012 Beijing, China March 13, 2013 Mr. Alan Lai, Agria's Chairman of the Board, commented, I am pleased to see continued improvement inPGWs performance year on year. PGW reported improved profits and strong net cash inflow from operating and investing activities which led to]

By | 2016-01-10T15:11:41+00:00 March 13th, 2013|Categories: Chinese Stocks, GRO, Webplus ver|Tags: , , , , , |0 Comments

EJ [E-HOUSE (CHINA)] 6-K: E-House Reports Fourth Quarter and Full Year 2012

[E-House Reports Fourth Quarter and Full Year 2012 Results and Declares Cash Dividend SHANGHAI, China, March 12, 2013 — E-House (China) Holdings Limited (“E-House” or the “Company”) (NYSE: EJ), a leading real estate services company in China, today announced its unaudited financial results for the fiscal quarter and full year ended December 31, 2012, and declared a cash dividend of] [E-HOUSE (CHINA) HOLDINGS LIMITED 17/F, East Tower No. 333 North Chengdu Road Shanghai 200041 People’s Republic of China Form 20-F x Form 40-F o o o E-House (China) Holdings Limited Bin Laurence]

CBPO [China Biologic Products] 8-K: (Original Filing)

[China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012 FY12 Total Sales Up 20.7% to $184.8 Million FY12 Operating Margin Reaching 40.3% FY12 Non-GAAP Net Income Up 31.5% to $48.0 Million BEIJING, March 13, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 8, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China 86-10-6698-3166 (Former name or former address,]

GSOL [GLOBAL SOURCES] 6-K: (Original Filing)

[Press Contact in Asia Investor Contact in Asia Camellia So Connie Lai Tel: (852) 2555-5021 Tel: (852) 2555-4747 e-mail: cso@globalsources.com e-mail: investor@globalsources.com Press Contact in U.S. Investor Contact in U.S. Brendon Ouimette Cathy Mattison Tel: (1-480) 664-8309 LHA e-mail: bouimette@globalsources.com Tel: (1-415) 433-3777 e-mail: cmattison@lhai.com Global Sources realigns real estate holdings NEW YORK, March 12, 2013 – (NASDAQ: GSOL) has]

By | 2016-03-07T17:23:56+00:00 March 13th, 2013|Categories: Chinese Stocks, GSOL, SEC Original|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 8-K: China Biologic Reports Financial Results for the Fourth

[China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012 FY12 Total Sales Up 20.7% to $184.8 Million FY12 Operating Margin Reaching 40.3% FY12 Non-GAAP Net Income Up 31.5% to $48.0 Million BEIJING, March 13, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 8, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China 86-10-6698-3166 (Former name or former address,]

JASO [JA Solar] 6-K: (Original Filing)

[JA Solar to Host Fourth Quarter and Full Year 201 2 Results Conference Call on March 2 5 , 201 3 Shanghai, March 11 , 201 3 — JA Solar Holdings Co., Ltd. (Nasdaq:JASO) (“JA Solar” or the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced that it will hold a conference call on]

By | 2016-03-08T09:46:28+00:00 March 13th, 2013|Categories: Chinese Stocks, JASO, SEC Original|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 10-K: (Original Filing)

[FORM 10-K (Mark One) December 31, 2012 For the fiscal year ended: For the transition period from ____________to _____________ Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 18th Floor, Jialong International Building, 19 Chaoyang Park Road (+86) 10-6598-3111 Title of each class Name of each exchange] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in registration statements (No. 333-171069 and 333-182624) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 13, 2013, with respect to the consolidated balance sheets of China Biologic Products,] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang (Principal Financial and Accounting Officer)]

JASO [JA Solar] 6-K: JA Solar to Host Fourth Quarter and Full

[JA Solar to Host Fourth Quarter and Full Year 201 2 Results Conference Call on March 2 5 , 201 3 Shanghai, March 11 , 201 3 — JA Solar Holdings Co., Ltd. (Nasdaq:JASO) (“JA Solar” or the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced that it will hold a conference call on]

By | 2016-03-08T09:47:32+00:00 March 13th, 2013|Categories: Chinese Stocks, JASO, Webplus ver|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 10-K: FORM 10-K (Mark One) December 31, 2012 For

[FORM 10-K (Mark One) December 31, 2012 For the fiscal year ended: For the transition period from ____________to _____________ Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 18th Floor, Jialong International Building, 19 Chaoyang Park Road (+86) 10-6598-3111 Title of each class Name of each exchange] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in registration statements (No. 333-171069 and 333-182624) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 13, 2013, with respect to the consolidated balance sheets of China Biologic Products,] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang (Principal Financial and Accounting Officer)]

Skip to toolbar